Next-generation off-the-shelf and precision viral vector neoantigen cancer immunotherapies

Marina joined Nouscom in 2016 from Versant Ventures. Before Versant, she headed up the Global Neurodegeneration portfolio for Novartis Neuroscience and lead development of companion diagnostics for Novartis Oncology. She received her Ph.D. in Organic Chemistry from Yale University.

Elisa was formerly a Research Scientist at IRBM/Merck, where she worked on immunological aspects of Hepatitis C infection and was subsequently appointed Group Leader in Oncology. She joined Okairos in 2010 as Clinical Director of the infectious disease vaccine programmes.

Sven joined Nouscom as Vice President Clinical Development in October 2021. Prior to joining the company, Sven held Senior Clinical Development positions in oncology at Incyte, Novartis, OSI Pharmaceuticals and AstraZeneca. Previously he held an academic position at the University Health Network in Toronto, Canada

Rick joined Nouscom in September 2020 from Johnson and Johnson Innovation where he was the Global Oncology Transaction Lead responsible for external collaborations and licensing of transformational preclinical assets. Previously he had responsibility for direct healthcare investments at Wellcome Trust, and has led business and corporate development for private and public biotechnology companies.

Tiffany has 15 years of experience in finance including investments, global treasury, and investor relations. Prior to joining Nouscom in 2019, she held leadership roles with a U.S. based Fortune 500 company where she oversaw complex finance facilities and debt issuances, managed large hedge portfolios, and cultivated investor relationships. Tiffany received her B.A. and M.A. in Mathematics.

Loredana was GMP head at Okairos/ Reithera since 2010 where she oversaw all the manufacturing campaigns for the production of APIs for both infectious diseases  and advanced therapies. With extensive experience in developing technical operations conducted in compliance with Good Manufacturing Practice, she joined Nouscom in April 2020 as Technical Director.

Göran spent 35 years in the pharmaceutical industry as head of R&D and in general management. He is now board director and chairman of biotech companies in US, EU and Asia. He is a physician by training.

Guido has been closely involved in multiple biotech investments. He was previously Managing Director of EuroVentures, a Versant incubator. He is a physician with a specialty in neuro-psychiatry, and the co-author of over 100 peer-reviewed papers.

Joachim joined LSP in 2002, and is currently a Managing Partner and co-owner of the firm. He has facilitated the growth and development of a large number of companies by leveraging his scientific and pharmaceutical expertise, and extensive global network.

Genghis’ current and past board positions include: Avillion, GenSight Biologics, HBI, Novexel, Solexa, Synosia and Wilson Therapeutics, and several others. He identifies and invests in new businesses, and supports portfolio companies.

Scott joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. He has over three decades of healthcare management experience and has entered multiple drug candidates into clinical trials.

Marina joined Nouscom in 2016 from Versant Ventures. Before Versant, she headed up the Global Neurodegeneration portfolio for Novartis Neuroscience and lead development of companion diagnostics for Novartis Oncology. She received her Ph.D. in Organic Chemistry from Yale University.

Jean-Paul is a Director of Vaximm AG and a member on Curevac independent Advisory Board. He was instrumental in developing several licensed vaccines and served as the Head of Research at GSK Vaccines.

John has over 25 years of business development experience with some of the industry’s premier companies, including Genentech, Genzyme, Millennium Pharmaceuticals, MPM Capital, Biogen and currently Novo Nordisk.

Vincent has more than 25 years of oncology and immunology experience. His experience encompasses a broad and integrated approach to immunotherapy – from bench discovery through to regulatory and commercial activities.

Alfredo was previously Chief Executive Officer of Nouscom and co-founders and Chief Scientific Officer of Okairos. He led the preclinical and clinical development of several vaccines and monoclonal antibodies against various infectious diseases and human cancers.

Stefano co-founded Okairos, where he was Senior Director for Vector Development. He has overseen and directed GMP manufacturing campaigns for numerous clinical trials.

Antonella was a co-founder of Okairos and Director of Immunology. She is a named inventor on several patents, and contributed to the preclinical and clinical validation of multiple infectious disease vaccine programmes.

Cinzia Traboni is a Nouscom co-founder and R&D GMO Manager. Previously she was Head of Regulatory Affairs and she was responsible for the RA activities supporting clinical trials in thefield of cancer immunotherapy, in US and in EU. She was also Regulatory Affairs Head of Okairos, where she coordinated the company regulation submissions for multiple clinical trials in the field of vaccines to infectious diseases in EU.